SAFETY AND TOLERABILITY OF SUBCUTANEOUS TRASTUZUMAB AS A TREATMENT IN PATIENTS WITH EARLY HER 2 POSITIVE BREAST CANCER : EXPERIENCE OF A CANCER CENTER IN PERU

被引：0
|
作者：
Otoya, Iris
Valdivieso, Natalia
Morante, Zaida
Castaneda, Carlos
Neciosup, Silvia
Calderon, Monica
Gomez, Henry
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-17-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-17-08
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Tolerability of the combination of lapatinib and trastuzumab in older patients with HER2 positive metastatic breast cancer
    O'Connor, Tracey
    Soto-Perez-de-Celis, Enrique
    Blanchard, Suzette
    Chapman, Andrew
    Kimmick, Gretchen
    Muss, Hyman
    Luu, Thehang
    Waisman, James R.
    Li, Daneng
    Mortimer, Joanne
    Yuan, Yuan
    Somlo, George
    Stewart, Daphne
    Katheria, Vani
    Levi, Abrahm
    Hurria, Arti
    CANCER RESEARCH, 2018, 78 (04)
  • [32] COST-MINIMIZATION ANALYSIS OF TRASTUZUMAB INTRAVENOUS VERSUS TRASTUZUMAB SUBCUTANEOUS FOR THE TREATMENT OF PATIENTS WITH HER2+EARLY BREAST CANCER AND METASTATIC BREAST CANCER IN GREECE
    Mylonas, C.
    Kourlaba, G.
    Fountzilas, G.
    Skroumpelos, A.
    Maniadakis, N.
    VALUE IN HEALTH, 2014, 17 (07) : A640 - A641
  • [33] Single institute experience of treatment for metastatic HER2 positive breast cancer patients with trastuzumab deruxtecan
    Kojima, Yasuyuki
    Tsugawa, Koichiro
    ANNALS OF ONCOLOGY, 2021, 32 : S338 - S338
  • [34] Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study
    Jacquin, Jean-Philippe
    Uwer, Lionel
    Savignoni, Alexia
    Ferrero, Jean-Marc
    Lortholary, Alain
    Solub, David
    Delaporte, Flore
    Chalabi, Nassera
    Pibre, Sophie
    Belkacemi, Yazid
    BREAST, 2020, 49 : 1 - 7
  • [35] Trastuzumab deruxtecan in the treatment of adult patients with HER2-positive breast cancer
    Kufel-Grabowska, Joanna
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (05): : 377 - 381
  • [36] Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers
    Jackisch, C.
    Mueller, V.
    Dall, P.
    Neumeister, R.
    Park-Simon, T. -W.
    Ruf-Doerdelmann, A.
    Seiler, S.
    Tesch, H.
    Ataseven, B.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2015, 75 (06) : 566 - 573
  • [37] Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients
    Bighin, Claudia
    Pronzato, Paolo
    Del Mastro, Lucia
    FUTURE ONCOLOGY, 2013, 9 (07) : 955 - 957
  • [38] Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer - single institution experience
    Ban, M.
    Viculin, J.
    Tomic, S.
    Capkun, V.
    Strikic, A.
    Mise, B. Petric
    Utrobicic, I.
    Vrdoljak, E.
    NEOPLASMA, 2016, 63 (05) : 761 - 767
  • [39] An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
    Antonio Buendia, Jefferson
    Vallejos, Carlos
    Pichon-Riviere, Andres
    BIOMEDICA, 2013, 33 (03): : 411 - 417
  • [40] Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer
    Mark Sanford
    Targeted Oncology, 2014, 9 : 85 - 94
12345